NASDAQ:AAPG Ascentage Pharma Group International (AAPG) Stock Price, News & Analysis $26.48 +0.92 (+3.60%) As of 05/23/2025 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Ascentage Pharma Group International Stock (NASDAQ:AAPG) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AAPG alerts:Sign Up Key Stats Today's Range$25.42▼$26.5550-Day Range$17.70▼$26.4852-Week Range$16.50▼$26.55Volume19,849 shsAverage Volume62,291 shsMarket Capitalization$2.31 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingBuy Company OverviewAscentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.Read More… Receive AAPG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ascentage Pharma Group International and its competitors with MarketBeat's FREE daily newsletter. Email Address AAPG Stock News HeadlinesAscentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025May 22 at 8:15 PM | globenewswire.comIs Ascentage Pharma (AAPG) the Best Performing Healthcare Stock to Buy Now?May 12, 2025 | msn.com[INSIDE] Elon’s Next Move Could Send This AI Stock SoaringMissed Nvidia? This Under-the-Radar AI Stock Could Be Next Musk's AI empire is just beginning — and one overlooked company could be at the center of it all. We reveal everything in this exclusive Memorial Day webinar.May 24, 2025 | Behind the Markets (Ad)Ascentage Pharma Group International ADRApril 30, 2025 | morningstar.comAscentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with LisaftoclaxApril 28, 2025 | globenewswire.comHigh Growth Tech Stocks in Asia to Watch This April 2025April 25, 2025 | finance.yahoo.comAscentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and AlrizomadlinApril 23, 2025 | globenewswire.comAscentage Pharma Drugs Included in Chinese Society of Clinical Oncology GuidelinesApril 23, 2025 | finance.yahoo.comSee More Headlines AAPG Stock Analysis - Frequently Asked Questions How have AAPG shares performed this year? Ascentage Pharma Group International's stock was trading at $18.67 on January 1st, 2025. Since then, AAPG stock has increased by 41.8% and is now trading at $26.48. View the best growth stocks for 2025 here. When did Ascentage Pharma Group International IPO? Ascentage Pharma Group International (AAPG) raised $126 million in an initial public offering (IPO) on Friday, January 24th 2025. The company issued 7,325,000 shares at a price of $17.25 per share. When does the company's lock-up period expire? Ascentage Pharma Group International's lock-up period expires on Wednesday, July 23rd. Ascentage Pharma Group International had issued 7,325,000 shares in its public offering on January 24th. The total size of the offering was $126,356,250 based on an initial share price of $17.25. After the expiration of the company's lock-up period, company insiders and major shareholders will be able to sell their shares of the company. Who are Ascentage Pharma Group International's major shareholders? Top institutional investors of Ascentage Pharma Group International include Monashee Investment Management LLC (0.18%). How do I buy shares of Ascentage Pharma Group International? Shares of AAPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today5/23/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AAPG Previous SymbolNASDAQ:AAPG CIK2023311 WebN/A Phone86 512 8555 7777FaxN/AEmployees600Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$980.65 million Price / Sales2.35 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares87,068,000Free FloatN/AMarket Cap$2.31 billion OptionableN/A BetaN/A The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:AAPG) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredThe “black glass” breakthrough behind AI’s next leapAI is advancing fast… But there’s one problem almost no one’s talking about. Power.True Market Insiders | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredTrump Quietly Planning $15 Trillion Crypto ShockerMost investors are still unaware, but I believe a new White House action may have quietly opened the floodgate...Paradigm Press | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascentage Pharma Group International Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascentage Pharma Group International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.